Merck & Co., Inc. Hep C Combo Gets Breakthrough Status

Published: Oct 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck & Co Inc. (MRK: Quote) Tuesday said the U.S Food and Drug Administration, or FDA, has granted Breakthrough Therapy designation for its MK-5172/MK-8742 oral combination regimen indicated for treatment of chronic hepatitis C virus infection.

Help employers find you! Check out all the jobs and post your resume.

Back to news